The launch follows a CE Mark received in late 2024
Bausch + Lomb announced the commercial launch of its enVista Aspire monofocal and toric intraocular lenses (IOLs) in the European Union after receiving a CE Mark late last year.
According to the company, the enVista Aspire IOLs combine novel Intermediate Optimised optics, designed for a broader depth of focus, with the proven benefits of the enVista platform to “address vision needs in today’s modern, digital world.” The lens also features 3C technology (Controlled Curvature Change) which are designed to harmonise the geometric power profile outward between the central base power and power at the periphery.1,2
The company also states that, unlike conventional spherical monofocal IOLs and low-order aspheric IOLs, enVista Aspire utilises higher-order aspheric coefficients on the posterior surface of the lens for a broader range of vision.1,2
Luc Bonnefoy, president of surgical at Bausch + Lomb commented on the release of the enVista Aspire IOLs in a press release from the company.1
“Surgeons around the world have long known the benefits of the enVista platform,” said Bonnefoy, “In the US, where enVista Aspire is currently available, surgeons and their patients appreciate the features of these monofocal lenses that are designed for a broader depth of focus, and we look forward to offering that feature in Europe as part of our comprehensive IOL portfolio.”
The company also notes that the Aspire IOLs can treat astigmatism and allows surgeons to “broaden the treatable astigmatism range in cataract surgery to as low as <1.0D at the corneal plane.” In the US, it was the first and only Low-Cyl toric (1.25D) below 1.5D at the IOL plane commercially available.1,2